Sign in

    Hiroshi Wada

    Research Analyst at SMBC Nikko Securities

    Hiroshi Wada is an Equity Analyst at SMBC Nikko Securities Inc., specializing in Japanese pharmaceutical and biotechnology sectors. He provides coverage of major listed companies such as Sumitomo Pharma and Nippon Shinyaku, regularly contributing forecasts and performance analyses for shareholders and investors. With a professional network spanning over 59 industry connections, Wada has established expertise through continuous coverage and insight in the Tokyo investment community since at least 2024. His credentials and career history are focused on equity research, though specific metrics such as TipRanks rankings or securities licenses are not publicly disclosed.

    Hiroshi Wada's questions to TAKEDA PHARMACEUTICAL CO (TAK) leadership

    Hiroshi Wada's questions to TAKEDA PHARMACEUTICAL CO (TAK) leadership • Q3 2025

    Question

    Hiroshi Wada from SMBC Nikko Securities asked about the likelihood of Entyvio being included in the U.S. IRA price negotiations in 2028.

    Answer

    CEO Christophe Weber confirmed that Entyvio's inclusion in the IRA in 2028 is a possibility. He stated this potential outcome is the reason the company has maintained a peak sales forecast range of $7.5 billion to $9 billion for the product, as it accounts for this risk.

    Ask Fintool Equity Research AI